Tag: third quarter

SEOUL, South Korea, July 08, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading gaming company delivering exceptional player experiences across multiple genres, announced today that the Company entered into a Share Purchase and Transfer Agreement with Azerion Tech Holding B.V. to acquire WHOW Games GmbH, a social casino developer headquartered in Hamburg, Germany. The initial consideration for 100% ownership interest in WHOW Games is €55 million (approximately $64.7 million⁽¹⁾). An additional earn-out payment of up to €10 million, payable to Azerion at €5 million annually, is contingent upon WHOW Games meeting certain performance targets during each of the first and second year following the closing date. The acquisition will be financed through DoubleDown’s cash reserves and is expected to close during the third quarter of 2025.

SPRINGDALE, Ark., July 07, 2025 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) will release third quarter 2025 financial results on Monday, August 4, 2025. Management will host a conference call and webcast beginning at 9:00 a.m. Eastern Time (8:00 a.m. Central Time). A press release and supplemental materials will be issued before the market opens that morning.

LOS ANGELES, July 07, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) securities between May 2, 2024, to May 6, 2025, inclusive (the “Class Period”).

Disclosure of total number of voting rights and
number of shares forming the capital
as of June 30, 2025

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

Q3 Fiscal 2025 Revenues

CALGARY, Alberta, July 02, 2025 (GLOBE NEWSWIRE) -- NuVista Energy Ltd. (TSX:NVA, "NVA" or "NuVista") is providing revised guidance to our annual production volumes and reiterating our commitment to our shareholder return strategy. Due to continued delays in commissioning the Pipestone Gas Plant (“Pipestone Plant”) and additional required work discovered during a gas plant turnaround in the greater Wapiti area (“Wapiti Turnaround”), we now anticipate annual volumes to average approximately 83,000 Boe/d⁽¹⁾. The impact of the delays due to the Pipestone Plant and Wapiti Turnaround on annual production volumes is approximately 3,500 Boe/d and 6,000 Boe/d, respectively. Both third-party facilities are expected to be fully operational prior to September.